Brokerages Set HilleVax, Inc. (NASDAQ:HLVX) PT at $3.00

Shares of HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) have earned an average rating of "Hold" from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $3.00.

Separately, HC Wainwright reaffirmed a "neutral" rating and set a $2.00 price objective on shares of HilleVax in a research note on Monday, March 31st.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in shares of HilleVax by 61.6% during the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock worth $38,000 after purchasing an additional 6,916 shares in the last quarter. Ieq Capital LLC lifted its holdings in HilleVax by 71.1% during the fourth quarter. Ieq Capital LLC now owns 22,495 shares of the company's stock worth $47,000 after acquiring an additional 9,344 shares in the last quarter. Intech Investment Management LLC bought a new position in HilleVax during the fourth quarter worth about $26,000. JPMorgan Chase & Co. grew its stake in HilleVax by 1,376.8% in the fourth quarter. JPMorgan Chase & Co. now owns 207,151 shares of the company's stock valued at $429,000 after acquiring an additional 193,124 shares during the period. Finally, Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of HilleVax in the fourth quarter worth about $13,919,000. Institutional investors and hedge funds own 86.42% of the company's stock.

HilleVax Stock Down 0.5%

NASDAQ HLVX traded down $0.01 during trading hours on Friday, hitting $1.85. The company's stock had a trading volume of 325,746 shares, compared to its average volume of 447,237. HilleVax has a twelve month low of $1.34 and a twelve month high of $15.29. The firm has a market capitalization of $92.76 million, a P/E ratio of -0.86 and a beta of 0.74. The stock has a fifty day moving average of $1.86 and a 200 day moving average of $1.85.

HilleVax (NASDAQ:HLVX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.25. On average, analysts predict that HilleVax will post -2.64 earnings per share for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.